Australia's Imugene rises on U.S. patent grant for its immunotherapy product

Imugene

10/02/2023 24:41

** Shares of Imugene Ltd  IMU.AX  rise as much as 7.4% to
A$0.145, their highest since Feb. 6
    ** The pharmaceutical company says it got a notice of
allowance from U.S. Patent and Trademark Office on patent
application for immunotherapy for non-small cell lung cancer
    ** Adds that the its PD1-Vaxx product is currently in
clinical development with final preparations in place for a
clinical trial
    ** YTD, IMU down about 7%
 (Reporting by Savyata Mishra in Bengaluru)
 ((Savyata.Mishra@thomsonreuters.com))